Amifampridine
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
- Amifampridine
- Pharmacist Assessment Report
- Amifampridine: Voltage-gated potassium channel blocker → Glaucoma (glaucoma)
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Amifampridine: Voltage-gated potassium channel blocker → Glaucoma (glaucoma)
One-Sentence Summary
Amifampridine is a potassium channel blocker that is marketed in Australia as an oral tablet. The TxGNN model predicts it may be useful for glaucoma with a score of 0.9971, but there are currently no clinical trials and no publications supporting this prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Glaucoma (glaucoma) |
| TxGNN Prediction Score | 0.9971 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data are not available in the data compiled for this report. Based on general pharmacology, amifampridine (3,4-diaminopyridine) blocks voltage-gated potassium channels. This prolongs presynaptic depolarisation and increases acetylcholine release at the neuromuscular junction.
A theoretical link to glaucoma could involve potassium channel modulation in retinal ganglion cells or the trabecular meshwork, or a neuroprotective effect. However, potassium channel blockade can also raise neuronal excitability, and there is no established benefit in optic neuropathy. The high TxGNN score is a computational output only. No mechanism-specific data were supplied to support it, so the relevance remains speculative.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 13032X | Ruzurgi | Tablet 10 mg | Not recorded in the local data |
Safety Considerations
Drug Interactions: The interaction screening returned 68 recorded interactions. Examples include:
- Major: bupropion
- Moderate: corticosteroids (hydrocortisone, betamethasone, dexamethasone, prednisolone, prednisone), levofloxacin, metoclopramide, opioids (morphine, opium), ephedrine, and anorectic or stimulant agents (phentermine, fenfluramine, dexfenfluramine, diethylpropion, mazindol, sibutramine), dronabinol, and polyethylene glycol with electrolytes
General pharmacology also suggests that amifampridine lowers the seizure threshold, so co-administration with agents that do the same needs particular care.
Please refer to the TGA-approved Product Information (PI) for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The glaucoma prediction has no supporting clinical trials or publications and no mechanism-specific data, so evidence is limited to model output (L5). The possible link to potassium channel modulation is speculative, and a potassium channel blocker may raise neuronal excitability.
To proceed, the following is needed:
- Mechanism of action data for amifampridine
- Preclinical evidence of a benefit in glaucoma models (for example, retinal ganglion cell protection or intraocular pressure effects)
- Warnings and contraindications from the TGA-approved PI, with a seizure-risk assessment
- An assessment of ocular route feasibility, since only an oral tablet is currently registered
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.